BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31578525)

  • 1. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.
    Yoshimi A; Lin KT; Wiseman DH; Rahman MA; Pastore A; Wang B; Lee SC; Micol JB; Zhang XJ; de Botton S; Penard-Lacronique V; Stein EM; Cho H; Miles RE; Inoue D; Albrecht TR; Somervaille TCP; Batta K; Amaral F; Simeoni F; Wilks DP; Cargo C; Intlekofer AM; Levine RL; Dvinge H; Bradley RK; Wagner EJ; Krainer AR; Abdel-Wahab O
    Nature; 2019 Oct; 574(7777):273-277. PubMed ID: 31578525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Aberrant RNA splicing and development of hematological malignancies].
    Yoshimi A
    Rinsho Ketsueki; 2020; 61(6):634-642. PubMed ID: 32624537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.
    Liang Y; Tebaldi T; Rejeski K; Joshi P; Stefani G; Taylor A; Song Y; Vasic R; Maziarz J; Balasubramanian K; Ardasheva A; Ding A; Quattrone A; Halene S
    Leukemia; 2018 Dec; 32(12):2659-2671. PubMed ID: 29858584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
    Rahman MA; Lin KT; Bradley RK; Abdel-Wahab O; Krainer AR
    Genes Dev; 2020 Mar; 34(5-6):413-427. PubMed ID: 32001512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
    Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O
    Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
    Shih AH; Meydan C; Shank K; Garrett-Bakelman FE; Ward PS; Intlekofer AM; Nazir A; Stein EM; Knapp K; Glass J; Travins J; Straley K; Gliser C; Mason CE; Yen K; Thompson CB; Melnick A; Levine RL
    Cancer Discov; 2017 May; 7(5):494-505. PubMed ID: 28193779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
    Hou HA; Liu CY; Kuo YY; Chou WC; Tsai CH; Lin CC; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Tien HF
    Oncotarget; 2016 Feb; 7(8):9084-101. PubMed ID: 26812887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C.
    Skrdlant L; Stark JM; Lin RJ
    BMC Mol Biol; 2016 Aug; 17(1):18. PubMed ID: 27552991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
    Sasaki M; Knobbe CB; Munger JC; Lind EF; Brenner D; Brüstle A; Harris IS; Holmes R; Wakeham A; Haight J; You-Ten A; Li WY; Schalm S; Su SM; Virtanen C; Reifenberger G; Ohashi PS; Barber DL; Figueroa ME; Melnick A; Zúñiga-Pflücker JC; Mak TW
    Nature; 2012 Aug; 488(7413):656-9. PubMed ID: 22763442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
    Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
    Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
    Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
    J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways.
    Magotra M; Sakhdari A; Lee PJ; Tomaszewicz K; Dresser K; Hutchinson LM; Woda BA; Chen BJ
    Histopathology; 2016 Dec; 69(6):1055-1065. PubMed ID: 27458708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Srsf2
    Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
    Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.
    Bamopoulos SA; Batcha AMN; Jurinovic V; Rothenberg-Thurley M; Janke H; Ksienzyk B; Philippou-Massier J; Graf A; Krebs S; Blum H; Schneider S; Konstandin N; Sauerland MC; Görlich D; Berdel WE; Woermann BJ; Bohlander SK; Canzar S; Mansmann U; Hiddemann W; Braess J; Spiekermann K; Metzeler KH; Herold T
    Leukemia; 2020 Oct; 34(10):2621-2634. PubMed ID: 32358566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia.
    Jia W; Guo X; Wei Y; Liu J; Can C; Wang R; Yang X; Ji C; Ma D
    Mol Biol Rep; 2023 Aug; 50(8):6601-6610. PubMed ID: 37344641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.
    Kats LM; Reschke M; Taulli R; Pozdnyakova O; Burgess K; Bhargava P; Straley K; Karnik R; Meissner A; Small D; Su SM; Yen K; Zhang J; Pandolfi PP
    Cell Stem Cell; 2014 Mar; 14(3):329-41. PubMed ID: 24440599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
    Wong JJ; Lau KA; Pinello N; Rasko JE
    Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
    Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
    Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution.
    Wu SJ; Kuo YY; Hou HA; Li LY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Lin CT; Chen CY; Chou WC; Yao M; Huang SY; Ko BS; Tang JL; Tsay W; Tien HF
    Blood; 2012 Oct; 120(15):3106-11. PubMed ID: 22932795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.